文献速递糖尿病

BRIGHT试验:Gla-300与IDeg-100在胰岛素初治2型糖尿病中疗效相似

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
PubMed 文献 · Diabetes Care · 2018-08-13

BRIGHT是一项多中心、开放标签、活性对照、两组平行、24周的非劣效性研究,纳入胰岛素初治且血糖控制不佳的2型糖尿病患者,随机1:1接受Gla-300(N=466)或IDeg-100(N=463)晚间给药,滴定至空腹自测血糖80-100 mg/dL。主要终点为24周HbA1c自基线变化,结果显示Gla-300非劣于IDeg-100;24周低血糖发生率与事件率两者相当,但在0-12周滴定期内Gla-300的任何时间(24小时)确认低血糖(≤70和<54 mg/dL)发生率和事件率更低。

要点

  • 24周HbA1c自基线改善程度Gla-300与IDeg-100相似,Gla-300非劣效于IDeg-100。
  • 24周低血糖发生率和事件率两种胰岛素相当,滴定期(0-12周)Gla-300更低。
  • 两种胰岛素滴定充分,未观察到特定安全性问题。

核心结论

  • Gla-300与IDeg-100提供相似的血糖控制改善,低血糖风险相对较低。
  • 全研究期间低血糖发生率和事件率两种胰岛素相当,但滴定期Gla-300更低。
  • 两种长效基础胰岛素的选择可能由可及性和成本等因素以及临床考虑决定。

研究设计与样本

  • BRIGHT(NCT02738151)为多中心、开放标签、活性对照、两组平行、24周的非劣效性研究。
  • 纳入胰岛素初治且血糖控制不佳的2型糖尿病患者,随机1:1晚间给药Gla-300(N=466)或IDeg-100(N=463),滴定至空腹自测血糖80-100 mg/dL。
  • 主要终点为HbA1c自基线至第24周的变化。

主要发现

  • 第24周HbA1c自基线8.7%(72 mmol/mol)的Gla-300组和8.6%(70 mmol/mol)的IDeg-100组均改善至7.0%(53 mmol/mol),最小二乘均数差-0.05%(95% CI -0.15至0.05)(-0.6 mmol/mol [-1.7至0.6]),证明Gla-300非劣效于IDeg-100(P < 0.0001)。
  • 24周低血糖发生率和事件率两种胰岛素相当。
  • 在0-12周主动滴定期内,Gla-300的任何时间(24小时)确认低血糖(≤70和<54 mg/dL)发生率和事件率低于IDeg-100。
  • 两种胰岛素滴定充分,未显示特定安全性问题。

临床怎么用

  • Gla-300和IDeg-100均可用于胰岛素初治2型糖尿病,提供相似的血糖控制改善且低血糖风险相对较低。
  • 滴定期Gla-300的低血糖发生率和事件率更低。
  • 两种长效基础胰岛素的选择可能由可及性和成本等因素以及临床考虑决定。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare insulin glargine 300 units/mL (Gla-300) versus insulin degludec 100 units/mL (IDeg-100) in this first head-to-head randomized controlled trial. RESEARCH DESIGN AND METHODS: BRIGHT (NCT02738151) was a multicenter, open-label, active-controlled, two-arm, parallel-group, 24-week, noninferiority study in insulin-naive patients with uncontrolled type 2 diabetes. Participants were randomized 1:1 to evening dosing with Gla-300 (N = 466) or IDeg-100 (N = 463), titrated to fasting self-monitored plasma glucose of 80-100 mg/dL. The primary end point was HbA1c change from baseline to week 24. Safety end points included incidence and event rates of hypoglycemia. RESULTS: At week 24, HbA1c improved similarly from baseline values of 8.7% (72 mmol/mol) in the Gla-300 group and 8.6% (70 mmol/mol) in the IDeg-100 group to 7.0% (53 mmol/mol)-least squares mean difference -0.05% (95% CI -0.15 to 0.05) (-0.6 mmol/mol [-1.7 to 0.6])-demonstrating noninferiority of Gla-300 versus IDeg-100 (P < 0.0001). Hypoglycemia incidence and event rates over 24 weeks were comparable with both insulins, whereas during the active titration period (0-12 weeks) the incidence and rate of anytime (24-h) confirmed hypoglycemia (≤70 and <54 mg/dL) were lower with Gla-300. Both insulins were properly titrated and exhibited no specific safety concerns. CONCLUSIONS: Gla-300 and IDeg-100 provided similar glycemic control improvements with relatively low hypoglycemia risk. Hypoglycemia incidence and rates were comparable with both insulins during the full study period but lower in favor of Gla-300 during the titration period. The choice between these longer-acting basal insulins may be determined by factors such as access and cost, alongside clinical considerations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Cheng A, Ritzel R, et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018. PMID: 30104294. doi:10.2337/dc18-0559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。